Project Optimus: helping or hindering cancer drug development? [Yahoo! Finance]
Blueprint Medicines Corporation (BPMC)
Last blueprint medicines corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
blueprintmedicines.com
Company Research
Source: Yahoo! Finance
implementation efforts in a bid to drive innovation in drug development. Agency eyes have zeroed in on oncology, with the FDA Oncology Center of Excellence (OCE) introducing frameworks such as Project Optimus to reform the dose optimization and dose selection paradigm in oncology drug development. While the framework of Optimus is not new to drug development, it is relatively new to oncology. In non-deadly indications, researchers have been employing the framework for quite some time because the chances of patient survival are higher, making drug toxicity less acceptable in these indications compared to a high-morbidity indication such as cancer, says Dr. Fouad Namouni, President of Research & Development at Blueprint Medicines. The philosophy of oncology drug development—both academically and in pharma—is to save patient lives. However, development has historically prioritised drug efficacy and eliminating the tumour and cancer at the expense of increased treatment toxicities. Th
Show less
Read more
Impact Snapshot
Event Time:
BPMC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BPMC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BPMC alerts
High impacting Blueprint Medicines Corporation news events
Weekly update
A roundup of the hottest topics
BPMC
News
- Blueprint Medicines Co. (NASDAQ: BPMC) is now covered by analysts at Stephens. They set an "overweight" rating and a $140.00 price target on the stock.MarketBeat
- Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update [Yahoo! Finance]Yahoo! Finance
- Blueprint Medicines Co. (NASDAQ: BPMC) was upgraded by analysts at Leerink Partnrs from an "underperform" rating to a "market perform" rating.MarketBeat
- Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $121.00 to $168.00. They now have a "buy" rating on the stock.MarketBeat
BPMC
Earnings
- 5/2/24 - Beat
BPMC
Sec Filings
- 5/15/24 - Form 144
- 5/15/24 - Form 144
- 5/10/24 - Form 4
- BPMC's page on the SEC website